UA138972U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, in which a clinical examination, radiography. Additionally, the patient's serum polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), endothelin, folic acid, cartilaginous oligomeric matrix protein (SOMC-67 and SOMP) 10 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEK) is determined in the patient's blood serum

C677tT), nitric oxide synthase (EeMO5 T786C), content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP). With homozygous carrier 677-171, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, SOMR" 595 ng/ml predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEK C677tT, eMmo5 T786C genes is determined, and the content of endothelin, folic acid, and SOMR are determined by the immunoenzymatic method. With homozygous carriers of 677-HT, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, SOMR" 595 ng/ml predict the development of osteoarthritis.

A specific example of using the method.

Patient G., 56 years old, was admitted to the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEK C677tT and emoz T786C genes was determined in blood serum. The content of endothelin, folic acid, SOMP was determined by immunoenzymatic method. Established homozygous carrier 677-

TT and 786-SS, levels of endothelin - 23 ng/ml, folic acid - 3.8 ng/ml, COMP - 770 ng/ml.

The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed phenomena

Koo) osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, in which a clinical examination and radiography are performed, which is distinguished by the fact that the polymorphism of the genes methylenetetrahydrofolate reductase (MINEV Сб677Т), nitric oxide synthase (emo5 T786С), the content of endothelin, folic acid, cartilage oligomeric matrix protein is additionally determined in the patient's blood serum (COMP) and homozygous carriers of 677-TT, 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, COMP" 595 ng/ml predict the development of osteoarthritis.